Journal
TRENDS IN CANCER
Volume 7, Issue 1, Pages 48-56Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2020.09.002
Keywords
-
Categories
Funding
- NIH [CA18029-39, CA225517-01]
- Damon Runyon Cancer Research Foundation
- Fred Hutchinson Cancer Research Center Evergreen Fund
- MPN Research Foundation
- Swiss National Science Foundation Advanced Postdoc Mobility Fellowship
- SAKK/Dr Paul Janssen Fellowship
- Emerson Collective
Ask authors/readers for more resources
Adoptively transferred TCR-transgenic T cells are not restricted by cell surface expression of targets and have the potential to play a key role in cellular cancer immunotherapies. By selecting ideal TCRs, enhancing TCR-T function, expansion, memory formation, and gene-engineering strategies, novel TCR-T therapies can be efficiently deployed.
Adoptively transferred T cell receptor (TCR)-transgenic T cells (TCR-T cells) are not restricted by cell surface expression of their targets and are therefore poised to become a main pillar of cellular cancer immunotherapies. Addressing clinical and laboratory data, we discuss emerging features for the efficient deployment of novel TCR-T therapies, such as selection of ideal TCRs targeting validated epitopes with well-characterized cancer cell expression and processing, enhancing TCR-T effector function, trafficking, expansion, persistence, and memory formation by strategic selection of substrate cells, and gene-engineering with synthetic co-stimulatory circuits. Overall, a better understanding of the relevant mechanisms of action and resistance will help prioritize the vast array of potential TCR-T optimizations for future clinical products.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available